Tag: study

VANCOUVER, BC, July 23, 2025 /CNW/ - Getchell Gold Corp. (CSE: GTCH) (OTCQB: GGLDF) (FWB: GGA1) ("Getchell" or the "Company") is pleased to announce...

ACE-Commissioned Report Analyzes Exposure to Malware, Phishing, and Other Cyber Harms Associated with Piracy Use in Southeast Asia SINGAPORE, July 23, 2025 /PRNewswire/ -- A...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

82km of drilling and $9M invested in resource development and exploration in Q4, FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited...

ASX Release $132M Treasury Build in Q4 FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited (ASX | TSX: WGX - Westgold or the Company) is pleased to report results...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

130 Breast Cancer Patients and Survivors Served During Five-Day Distribution of Donated Essentials TALLAHASSEE, Fla., July 22, 2025 /PRNewswire/ -- United Breast Cancer Foundation (UBCF)...

Sparkling Ice and Giant Eagle have teamed up to sponsor a PTSD service dog through K9s For Warriors, whose mission is to end veteran suicide.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Plant Tissue Culture Market size & share revenue was valued at approximately USD 525.98 Million in 2024 and is expected to reach USD 570.61 Million in 2025 and is expected to reach around USD 1,205.94 Million by 2034, at a CAGR of 8.67% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Phytoclone Inc., Melford Laboratories, Lifesible, Labland Biotech Private Limited, Knight Hollow Nursery, IribovSBW, HIMEDIA LABORATORIES, DP-Deroose Plants, Dark Heart Nursery, Caisson Laboratories, Inc., Booms Pharm, Alpha Laboratories, AgriStarts, AgriForest Bio-Technologies, 3 Rivers Biotech and others.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Plant Tissue Culture Market size & share revenue was valued at approximately USD 525.98 Million in 2024 and is expected to reach USD 570.61 Million in 2025 and is expected to reach around USD 1,205.94 Million by 2034, at a CAGR of 8.67% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Phytoclone Inc., Melford Laboratories, Lifesible, Labland Biotech Private Limited, Knight Hollow Nursery, IribovSBW, HIMEDIA LABORATORIES, DP-Deroose Plants, Dark Heart Nursery, Caisson Laboratories, Inc., Booms Pharm, Alpha Laboratories, AgriStarts, AgriForest Bio-Technologies, 3 Rivers Biotech and others.

BOSTON, July 22, 2025 /PRNewswire/ -- In a new article published in Value in Health, researchers from Analysis Group, a global leader in health economics...

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

The gap between dealers' perceived industry momentum and auto-buyers' hesitation widens DETROIT, July 22, 2025 /PRNewswire/ -- Urban Science®, a global automotive consultancy and technology...